Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice

Nature Communications

Volumn 7, Issue , 2016, Pages

  Han, Gang ^a   Gu, Ben ^a   Cao, Limin ^a   Gao, Xianjun ^a   Wang, Qingsong ^a   Seow, Yiqi ^b   Zhang, Ning ^a   Wood, Matthew J A ^c   Yin, HaiFang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Agency for Science   (Singapore)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARABINOSE; DYSTROPHIN; FRUCTOSE; GALACTOSE; GLUCOSE; HEXOSE; MANNOSE; MORPHOLINO OLIGONUCLEOTIDE; SORBITOL; XYLITOL; ANTISENSE OLIGONUCLEOTIDE; APO-DYSTROPHIN 1; MESSENGER RNA;

BIOCHEMISTRY; CARBOHYDRATE; DISEASE; ENZYME ACTIVITY; GLUCOSE; METABOLISM; MOLECULAR ANALYSIS; MUSCLE; RODENT; SKELETON;

ABDOMINAL WALL MUSCULATURE; ACTIVE TRANSPORT; ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ENERGY; CELL METABOLISM; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GASTROCNEMIUS MUSCLE; GENE TARGETING; GLUCOSE METABOLISM; GRIP STRENGTH; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; ANIMAL; DRUG EFFECTS; EXON; GENE THERAPY; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; RNA SPLICING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; DYSTROPHIN; EXONS; FRUCTOSE; GENETIC THERAPY; GLUCOSE; HEXOSES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED MDX; MORPHOLINOS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING; RNA, MESSENGER;

EID: 84960886786     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10981     Document Type: Article

References (35)

1. Bonilla, E. et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 54, 447-452 (1988).
2. Goemans, N. M. et al. Systemic administration of PRO051in duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522 (2011).
3. Cirak, S. et al. Exon skipping and dystrophin restoration in patients with duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-Label, phase 2, dose-escalation study. Lancet 378, 595-605 (2011).
4. Lu, Q. L. et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci USA 102, 198-203 (2005).
5. Alter, J. et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177 (2006).
6. Goyenvalle, A. et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med. 21, 270-275 (2015).
7. Gebski, B. L., Mann, C. J., Fletcher, S. & Wilton, S. D. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12, 1801-1811 (2003).
8. Yin, H. et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiacdystrophin expression and function. Hum. Mol. Genet. 17, 3909-3918 (2008).
9. Wu, B. et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA 105, 14814-14819 (2008).
10. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341-345 (2011).
11. Kumar, P. et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43 (2007).
12. Schein, P. S. & Bates, R. W. Plasma glucose levels in normal and adrenalectomized mice treated with streptozotocin and nicotinamide. Diabetes 17, 760-765 (1968).
13. Wu, B. et al. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol. Ther. 19, 576-583 (2011).
14. Nowak, K. J. & Davies, K. E. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 5, 872-876 (2004).
15. Ozawa, E., Hagiwara, Y. & Yoshida, M. Creatine kinase, cell membrane and Duchenne muscular dystrophy. Mol. Cell Biochem. 190, 143-151 (1999).
16. Narita, S. & Yorifuji, H. Centrally nucleated fibers (CNFs) compensate the fragility of myofibers in mdx mouse. Neuroreport 10, 3233-3235 (1999).
17. Brazeau, G. A., Mathew, M. & Entrikin, R. K. Serum and organ indices of the mdx dystrophic mouse. Res. Commun. Chem. Pathol. Pharmacol. 77, 179-189 (1992).
18. Kendall, G. C. et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of duchenne muscular dystrophy. Sci. Transl. Med. 4, 164ra160 (2012).
19. Mann, C. J., Honeyman, K., McClorey, G., Fletcher, G. & Wilton, S. D. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4, 644-654 (2002).
20. Betz, A. L., Drewes, L. R. & Gilboe, D. D. Inhibition of glucose transport into brain by phlorizin, phloretin and glucose analogues. Biochim. Biophys. Acta 406, 505-515 (1975).
21. Wegener, G. & Krause, U. Different modes of activating phosphofructokinase, a key regulatory enzyme of glycolysis, in working vertebrate muscle. Biochem. Soc. Trans. 30, 264-270 (2002).
22. Shchepina, L. A. et al. O. Oligomycin, inhibitor of the F0 part of H+-ATP synthase, suppresses the TNF-Induced apoptosis. Oncogene 21, 8149-8157 (2002).
23. Beis, I. & Newsholme, E. A. The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem. J. 152, 23-32 (1975).
24. Radley-Crabb, H. G. et al. Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of duchenne muscular dystrophy. PLoS ONE 9, e89277 (2013).
25. Satomura, S. et al. Paradoxical weight loss with extra energy expenditure at brown adipose tissue in adolescent patients with Duchenne muscular dystrophy. Metabolism 50, 1181-1185 (2001).
26. Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
27. Lehto, T. et al. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res. 42, 3207-3217 (2013).
28. Fujisawa, T., Riby, J. & Kretchmer, N. Intestinal absorption of fructose in the rat. Gastroenterology 101, 360-367 (1991).
29. Ushijima, K., Riby, J. E., Fujisawa, T. & Kretchmer, N. Absorption of fructose by isolated small intestine of rats is via a specific saturable carrier in the absence of glucose and by the disaccharidase-related transport system in the presence of glucose. J. Nutr. 125, 2156-2164 (1995).
30. Augustin, R. The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life 62, 315-333 (2010).
31. Wasserman, D. H., Kang, L., Ayala, J. E., Fueger, P. T. & Lee-Young, R. S. The physiological regulation of glucose flux into muscle in vivo. J. Exp. Biol. 214, 254-262 (2011).
32. Rodriguez-Cruz, M. et al. Evidence of insulin resistance and other metabolic alterations in boys with duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015).
33. Balaban, R. S. Metabolic homeostasis of the heart. J. Gen. Physiol. 139, 407-414 (2012).
34. Aoki, Y. et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum. Mol. Genet. 22, 4914-4928 (2013).
35. Tomonari, K. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 28, 455-458 (1988).